Posted by Michael Wonder on 29 Sep 2021
U.S. FDA approves Livmarli (maralixibat) as the first and only approved medication for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older
29 September 2021 - Mirum Pharmaceuticals today announced that the U.S. FDA has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Livmarli, a minimally absorbed ileal bile acid transporter inhibitor, is the first and only FDA approved medication in this rare liver disease which affects 2,000 to 2,500 children in the United States.
In conjunction with the approval, Mirum received a rare paediatric disease priority review voucher.
